CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of melanoma.
  
  LEARNING OBJECTIVES

  • Identify patients after the surgical removal of primary melanoma for whom adjuvant therapy should be considered, and counsel them regarding the risks and potential benefits of existing and recently approved systemic approaches.
  • Consider age, performance status and other disease-related factors in the selection of first- and later-line therapy for patients with metastatic BRAF wild-type or BRAF-mutated melanoma.
  • Use available clinical trial evidence to safely and effectively incorporate targeted and immunotherapeutic approaches into the management of metastatic melanoma with BRAF tumor mutations.
  • Recognize the FDA approval of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for patients with unresectable or metastatic melanoma with a BRAF V600 tumor mutation, and consider how the availability of this strategy affects current therapeutic algorithms.
  • Appreciate current evidence informing the selection of therapy for patients with advanced melanoma with BRAF mutations and brain metastases.
  • Identify the adverse events associated with immune checkpoint inhibitors, targeted therapies and other systemic treatments for melanoma, and offer supportive management strategies to minimize side effects.
  • Recall available and emerging data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies in combination with other systemic therapies (eg, targeted therapy, other immunotherapies) for advanced melanoma, and counsel appropriate patients about clinical trial availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Adil Daud, MD
  Director, Melanoma Program
  Clinical Professor of Medicine
  University of California, San Francisco
  San Francisco, California
  
  Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Genentech, a member of the Roche Group, Merck; Consulting Agreement: Merck; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Ownership Interest: OncoSec Medical.
  
  Michael Postow, MD
  Chief, Melanoma Service
  Associate Attending Physician
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: Aduro Biotech, Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Eisai Inc, Merck, Novartis; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Infinity Pharmaceuticals Inc, Merck, Novartis, Rgenix; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.
  
  Hussein Tawbi, MD, PhD
  Professor
  Deputy Chair, Department of Melanoma Medical Oncology
  Director of Melanoma Clinical Research and Early Drug Development
  Co-Director, MD Anderson Brain Metastasis Clinic
  Melanoma Medical Oncology, Investigational Cancer Therapeutics
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: Bristol-Myers Squibb Company, Eisai Inc, Genentech, a member of the Roche Group, Merck, Novartis; Contracted Research: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck, Novartis.
  
  Jeffrey S Weber, MD, PhD
  Deputy Director
  Laura and Isaac Perlmutter Cancer Center
  Professor of Medicine
  NYU Grossman School of Medicine
  New York, New York
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, Merck, Novartis, Pfizer Inc, Xencor; Contracted Research: NextCure; Data and Safety Monitoring Board/Committee: Pfizer Inc; Ownership Interest: ImmuniMax; Equity: Biond Biologics, CytomX Therapeutics, Protean LLC.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Pfizer Inc.
  
  Release date: January 2021
  Expiration date: January 2022